ERBB2 and breast carcinoma: Further subgroup analysis revealed that elevated ATP6V0D2 levels correlated with poorer outcomes in the LumA, LumB, and TNBC breast cancer subtypes, but not in HER2-enriched cases (Figures 2D–L).